IU researchers identify protein target that could lead to therapies for hard-to-treat cancers
Researchers at the Indiana University School of Medicine have identified a compound that targets a cancer-related protein, suggesting it could offer a future therapy for difficult-to-treat cancers. The protein, called SHP2, emerged as a potential new “druggable target” in research published online in Blood, the journal of the American Society of Hematology. Indiana University is home to the Melvin and Bren Simon Cancer Center.
Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.